References
- Haute Autorité de Santé. Décision n°2013.0111/DC/SEESP du 18 septembre 2013 du collège de la Haute Autorité de santé relatif à l’impact significatif sur les dépenses de l’assurance maladie déclenchant l’évaluation médico-économique des produits revendiquant une ASMR ou une ASA de niveaux I, II ou III. 2013. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-09/c_2013_0111_definition_impact_significatif.pdf
- Haute Autorité de Santé. Choix méthodologiques pour l’évaluation économique à la HAS. Saint-Denis La Plaine: HAS; 2011.
- Haute Autorité de Santé. Choices in methods for economic evaluation. 2012. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdf
- Brazier J, Ratcliffe J, Salomon JA, et al. Measuring and valuing health benefits for economic evaluation. New York (NY): Oxford University Press; 2007.
- Williams A. QALYS and ethics: a health economist’s perspective. Soc Sci Med. 1996 Dec;43(12):1795–1804.
- Beresniak A, Medina-Lara A, Auray JP, et al. Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project. Pharmacoeconomics. 2015 Jan;33(1):61–69.
- Mortimer D, Segal L. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making. 2008 Jan–Feb;28(1):66–89.
- Heintz E, Gerber-Grote A, Ghabri S, et al. Is there a European view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EUnetHTA partner countries. Pharmacoeconomics. 2016 Jan;34(1):59–76.
- International Society for Pharmacoeconomics and Outcomes Research [ISPOR]. Pharmacoeconomic guidelines around the world. 2013. Available from: http://www.ispor.org/PEguidelines/index.asp
- Chevalier J, De Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ. 2013 Feb;14(1):57–66.
- Le Gales C, Buron C, Costet N, et al. Development of a preference-weighted health status classification system in France: the Health Utilities Index 3. Health Care Manag Sci. 2002 Feb;5(1):41–51.
- Stein K, Fry A, Round A, et al. What value health? A review of health state values used in early technology assessments for NICE. Appl Health Econ Health Policy. 2005;4(4):219–228.
- Tosh JC, Longworth LJ, George E. Utility values in national institute for health and clinical excellence (NICE) technology appraisals. Value Health. 2011 Jan;14(1):102–109.
- Scuffham PA, Whitty JA, Mitchell A, et al. The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002–4. Pharmacoeconomics. 2008;26(4):297–310.
- Haute Autorité de Santé. Format de l’avis d’efficience. 2013. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-08/format_de_lavis.pdf.
- Brazier J, Rowen D NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values. Alternatives to EQ-5D for generating health state utility values. 2011. Available from: http://www.nicedsu.org.uk/TSD11%20Alternatives%20to%20EQ-5D_final.pdf.
- Ghabri S, Hamers FF, Josselin JM. Exploring uncertainty in economic evaluations of drugs and medical devices: lessons from the first review of manufacturers’ submissions to the French National Authority for Health. Pharmacoeconomics. 2016;34:617–624. DOI:10.1007/s40273-016-0381-4
- Brazier J. Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics. 2008;26(9):769–779.
- Papaioannou D, Brazier J, Paisley S. Systematic searching and selection of health state utility values from the literature. Value Health. 2013 Jun;16(4):686–695.
- Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
- Higgins JPT, Green S. Cochrane Handbook for systematic reviews of interventions (version 5.1.0). Oxford: Cochrane Collaboration; 2011.
- Garau M, Shah KK, Mason AR, et al. Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics. 2011 Aug;29(8):673–685.
- Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007 Winter;23(1):36–42.
- Hyry HI, Stern AD, Cox TM, et al. Limits on use of health economic assessments for rare diseases. QJM. 2014 Mar;107(3):241–245.
- Ara R, Wailoo A. Using health state utility values in models exploring the cost-effectiveness of health technologies. Value Health. 2012 Sep–Oct;15(6):971–974.
- Wisløff T, Hagen G, Hamidi V, et al. Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010. Pharmacoeconomics. 2014 Apr;32(4):367–375.
- Wolowacz SE, Briggs A, Belozeroff V, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016 Sep–Oct;19(6):704–719.